CPT code 0299U designates the Praxis Somatic Optical Genome Mapping test, a Proprietary Laboratory Analyses (PLA) assay that compares paired normal and malignant specimens to detect large-scale structural DNA changes associated with cancer. As a PLA code tied to a single manufacturer's assay, 0299U matters nationally because it enables specific reporting and tracking of a novel optical genome mapping (OGM) technology that may influence diagnostic pathways for hematologic and solid tumor evaluation.

Key payers covered in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical purpose of the test, typical sites of service, and the service type. The publication presents benchmarks and coverage policy context where available, summarizes payer approaches to PLA and emerging genomic technologies, and outlines clinical considerations relevant to oncology diagnostic workflows.

This report is intended for national audiences of payers, providers, and laboratory administrators seeking clarity on billing, coding, and the clinical role of a proprietary OGM-based somatic test. Data not available in the input is noted where applicable.